All News
Healthy diet helps chronic pain
d
EurekAlert!
Chronic pain is an acute and debilitating condition that affects millions of people worldwide. And while pain interventions are available, many people struggle without treatment at all.
Read Article
Way Behind in Pediatric Rheumatology
While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).
Read Article
Chikungunya marches on, at a cost
A recent article from BMC Global Health suggests that between 2011 and 2020, the mosquito-borne disease chikungunya, has disabled millions and likely amassed close to $50 billion in healthcare and disability-related costs in 110 countries.
Read Article
ICYMI: SELECT-GCA suggests JAKis may be the new kid on the block
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. A new group of drugs is finally showing promise in the treatment of GCA.
Read Article
Navigating Rheumatology Care in Humanitarian Crisis Settings
Dr. Antoni Chan talks with Dr. Martha Dhzhus, who presented Thursday at the Global Summit about rheumatology care in the Ukraine, at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/k4YTVFnTiF https://t.co/bScrJ28rKi
Dr. John Cush RheumNow ( View Tweet)
Metabolic syndrome assoc w/ with response rates in #RA (CDAI MCID OR 0.6), on or off TNFi. Adipokines were associated with metabolic syndrome but were not associated with clinical responses. Data from CERTAIN cohort & CorEvitas registry https://t.co/YH44iTwYTr https://t.co/ec3vb266ym
Dr. John Cush RheumNow ( View Tweet)
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
Dr. John Cush RheumNow ( View Tweet)
Summary of JAKi Studies
Dr. Peter Nash, at the 2024 ACR Convergence meeting in Washington, DC, talks about JAKi data presented in: the SELECT-GCA trial and safety signals; ILD; cancer; cycling; RA; uveitis; and new JAKs under study.
https://t.co/ywmtrTi0iF https://t.co/nbFFojL1i4
Dr. John Cush RheumNow ( View Tweet)
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index… https://t.co/qyZPDzUduO https://t.co/cCoc3sWCJy
Dr. John Cush RheumNow ( View Tweet)
Infertility linked to post-childbrith onset of systemic autoimmune disease
Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a… https://t.co/NJf44KJ2Hc https://t.co/W4rhsDHoqB
Dr. John Cush RheumNow ( View Tweet)
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/4Bz3Vq93jH https://t.co/ZhwKZ4XmNy
Dr. John Cush RheumNow ( View Tweet)
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/UbqVOr2iDx https://t.co/Ye5mYcbYX2
Dr. John Cush RheumNow ( View Tweet)
Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/dWvBjXgAIh https://t.co/YWmdqJrijf
Dr. John Cush RheumNow ( View Tweet)
Primary Hypophosphatemia (HYPOPH) - Japan study 50,136 adults w/ 424,434 alk phosphatase (ALP) tests. Persistent HYPOPH seen in 0.54% (273) due to cancer(30%), steroids(21%), DMARDs (16%). Unexplained HYPOPH had pain, muscle weakness, fatigue & could have primary HYPOPH… https://t.co/kGPSXSYEZI https://t.co/RtwSRnzeU0
Dr. John Cush RheumNow ( View Tweet)
Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab.https://t.co/SMKx1LnBB1 https://t.co/96u5YuvyIf
Dr. John Cush RheumNow ( View Tweet)
Ozempic will change rheumatology @drdavidliew
Ozempic is everywhere. Even all the way in Australia, where we have highly constrained supply that makes headlines and substantial limits on direct-to-consumer advertising, somehow I know the jingle from the American ad for Ozempic.… https://t.co/4gujykjDCa https://t.co/RLG1vA57kC
Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 inhibitor Zasocitinib
Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/KbHcgSIohv https://t.co/0g8X4zrq4X
Dr. John Cush RheumNow ( View Tweet)
ACR24 JAK TYK Topic Panel
https://t.co/SzurEICVxr https://t.co/m6cKyA4BBv
Dr. John Cush RheumNow ( View Tweet)
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush RheumNow ( View Tweet)
Inebilizumab for Treatment of IgG4-Related Disease
Inebilizumab is a monoclonal antibody that depletes CD19+ B cells and has been studied in adults with IgG4-related disease. In a phase 3, double-blind, randomized, placebo-controlled trial, it reduced IgG4-related disease… https://t.co/7PAmCn9O2I https://t.co/NmNA1p6GmI
Dr. John Cush RheumNow ( View Tweet)